Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen, Inc. | -2.36% | 275.24 | 1.4% | $809.20m | |
| AMGN | Amgen, Inc. | -0.56% | 217.00 | 1.3% | $492.24m | |
| CELG | Celgene Corp. | -0.47% | 109.89 | 1.3% | $454.55m | |
| GILD | Gilead Sciences, Inc. | 0.02% | 63.34 | 1.0% | $379.12m | |
| ILMN | Illumina, Inc. | 0.02% | 298.29 | 3.5% | $303.29m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.24% | 204.53 | 1.9% | $296.06m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.36% | 340.09 | 2.6% | $258.39m | |
| EXAS | EXACT Sciences Corp. | 2.09% | 79.89 | 24.0% | $198.96m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.62% | 105.40 | 2.0% | $180.23m | |
| SGEN | Seattle Genetics, Inc. | -0.18% | 112.01 | 6.1% | $131.31m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.73% | 75.58 | 4.3% | $115.39m | |
| SRPT | Sarepta Therapeutics, Inc. | -3.38% | 97.59 | 14.6% | $111.53m | |
| A | Agilent Technologies, Inc. | -0.35% | 76.89 | 1.6% | $100.75m | |
| MRTX | Mirati Therapeutics, Inc. | 1.65% | 102.39 | 2.3% | $88.04m | |
| NBIX | Neurocrine Biosciences, Inc. | -1.18% | 109.60 | 5.0% | $84.66m |
Company Profile
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.